MicroRNA-10b promotes migration and invasion through Hoxd10 in human gastric cancer by unknown
WORLD JOURNAL OF 
SURGICAL ONCOLOGY
Wang et al. World Journal of Surgical Oncology  (2015) 13:259 
DOI 10.1186/s12957-015-0673-8RESEARCH Open AccessMicroRNA-10b promotes migration and
invasion through Hoxd10 in human gastric cancer
Yuan-Yu Wang1*, Li Li2, Zai-Yuan Ye1, Zhong-Sheng Zhao3* and Zhi-Long Yan1Abstract
Background: This study aims to investigate the effect of miR-10b overexpression on cancer cell proliferation,
migration, invasion, and Hoxd10 expression.
Methods: The effect of miR-10b on proliferation, migration, and invasion of MKN-28, BGC-823, and SGC-7901 cells
and the expression of Hoxd10 protein in SGC-7901 and BGC-823 cells were detected following transfection of
miR-10b inhibitor or Negative Control B. Expression of Hoxd10 protein in 436 paraffin-embedded cancer tissues
was also investigated.
Results: miR-10b was significantly upregulated in AGS, MKN-28, BGC-823, HCG-27, SGC-7901, and MKN-45 cell
lines, miR-10b inhibitor significantly inhibited proliferation and migration of MKN-45, BGC-823 and SGC-7901 cells
48 h after transfection, while Hoxd10 protein in these cells lines had increased 72 h after transfection. Hoxd10
was highly expressed in gastric cancer and correlated with size of tumor, Lauren classification, depth of invasion,
lymph node and distant metastasis, Tumor-Node-Metastasis (TNM) stage, and prognosis.
Conclusions: miR-10b promotes migration and invasion through Hoxd10 in human gastric cancer cell lines and
may play an important role in tumorigenesis, progression, and prognosis.
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MicroRNAs (miRNAs) are a family of 21-to 25-nucleotide,
noncoding small RNAs that primarily function as gene reg-
ulators by regulating mRNA translation and degradation
[1]. miRNAs play a role in cancer or cancer prevention by
adjusting the expression of downstream mRNA [2]. Previ-
ous studies show that miR-10b is upregulated in liver, pan-
creatic, and esophageal cancer, breast cancer with distant
metastasis, and glioma tissues, and its expression is closely
related with tumor progression [3–7]. miR-10b promotes
migration and invasion through HOXD10, CADM1,
MAPRE1, and KLF4 et al. [5–10], but the exact regulatory
pathway is still poorly understood. However, nothing is
known about the role of miR-10b gastric cancer metastasis.
Therefore, in this study, we analyzed the level of miR-10b
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article, unless otherwise stated.823, HCG-27, SGC-7901, 9811P, and MKN-45 and in the
non-malignant gastric epithelial cell line GES-1, and the ef-
fect of miR-10b expression on gastric cancer cell prolifera-
tion, invasion, and migration. We aimed to elucidate the
role of miR-10b in gastric cancer formation, development,
invasion and metastasis, and its mechanism.Methods
Cell culture
Human gastric cancer cell lines AGS, MKN-28, BGC-823,
HCG-27, SGC-7901, 9811P, and MKN-45 and non-
malignant gastric epithelial cell line GES-1 were obtained
from Key Laboratory of Gastroenterology of Zhejiang
Province (Hangzhou, China) and cultured in RPMI1640
containing 10 % fetal bovine serum (FBS), 50 U/ml peni-
cillin, and 50 μg/ml streptomycin. All cells were main-
tained at 37 °C under an atmosphere of 5 % CO2.Archived gastric tissue samples and non-tumor mucosa
Gastric cancer tissues were collected from gastrectomy
specimens from 436 patients (311 male, 125 female,e is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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of Surgery, Zhejiang Provincial People’s Hospital, from
January 1998 to January 2004. Tissues were formalin-
fixed, paraffin-embedded, and diagnosed clinically and
histopathologically at the Departments of Gastrointestinal
Surgery and Pathology. The follow-up deadline was De-
cember 2008. The survival time was calculated from the
date of surgery to the follow-up deadline or date of death,
which was mainly due to carcinoma recurrence or metas-
tasis. There were 55, 163, and 218 cases from the cardia,
body, and antrum, respectively. According to the 2002
WHO histological classification of gastric carcinoma,
there were 326 tubular adenocarcinomas, 16 papillary
adenocarcinomas, 29 mucinous adenocarcinomas, and 65
signet-ring cell carcinomas. Thirteen were classified as
highly differentiated adenocarcinomas, 128 as well or
moderately differentiated adenocarcinomas, 293 as poorly
differentiated and 2 as undifferentiated adenocarcinomas.
There were 61 cases with distant metastasis. Ninety cases
were categorized as stage I, 104 as stage II, 173 as stage
III, and 69 as stage IV. Ninety-two noncancerous human
gastric tissues were obtained from gastrectomies of adja-
cent gastric cancer margins greater than 5 cm. Routine
chemotherapy was given to the patients with advanced
stage disease after surgery, but no radiation treatment was
administered to any patients included in our study.
RT-PCR quantification of miR-10b
RT-PCR was performed to determine the expression of
miR-10b. Briefly, total RNA was extracted from human
gastric cancer cell lines AGS, MKN-28, BGC-823, HCG-
27, SGC-7901, 9811P, MKN-45 and non-malignant gas-
tric epithelial cell line GES-1 using Trizol (Invitrogen)
according to the manufacturer’s instructions. cDNA syn-
thesis was carried out with the miScript Reverse Tran-
scription Kit (Qiagen). The specific reverse primer for
miR-10b and U6 were provided by Qiagen. The resulting
cDNA was amplified with the QuantiTect SYBR Green
PCR Master Mix (Qiagen) using ABI 7500 FAST Real-
time PCR (Applied Biosystems). PCR parameters were
as follows: 95 °C for 15 min, followed by 40 cycles of
94 °C for 15 s, 55 °C for 30 s, 72 °C for 34 s. At the end
of the PCR cycles, melting curve analysis was performed.
The expression of miR-10b in cancer tissues was com-
pared to matched normal samples using the 2-△△CT
method, and the expression of miR-10b in gastric cancer
cells was compared to GES-1.
miR-10b transfection
miR-10b inhibitor (miRCURY LNA™ microRNA Power
inhibitor, 5 nmol, 5′-fluorescein labeled, Exiqon) and
Negative Control B (miRCURY LNA™ microRNA Power
Inhibitor Negative Control B, 5 nmol, 5′-fluorescein la-
beled, Exiqon) were transfected into MKN-28, BGC-823,and SGC-7901 cells grown in six-well dishes (plated at
5.0 × 105 cells per well 24 h before transfection). Trans-
fection was performed with Lipofectamine 2000 (Invitro-
gen). Twenty-four hours after, transfection cells were
assayed for migration, invasion, and proliferation.
Cell proliferation assay
The effect of miR-10b on proliferation of gastric cancer
cells was evaluated by MTT assays. MKN-28, BGC-823,
and SGC-7901 cells were seeded into 96-well plates at a
density of 6.0 × 103 cells/well in quintuplicate and
allowed to adhere overnight. Ten microliters of MTT
(5 mg/ml) (Sigma) was added to each well 48 or 72 h
after infection, and cells were incubated for a further
4 h. Media was then removed, and 150 μl DMSO was
added. Absorbance (A) at 570 and 630 nm were mea-
sured using a microplate reader. Relative cell prolifera-
tion (%) was shown by the following equation: Relative
proliferation rate (%) = (A570nm–A630nm) of study group/
(A570nm–A630nm) of control group × 100 %.
In vitro cell migration and invasion assays
Twenty-four hours after infection, cells were harvested
and subjected to the following assays. For migration as-
says, infected cells (6 × 104) were plated in triplicate in
the top chamber of Transwells (Millicell Hanging Cell
Culture Inserts, PIEP12R48, Millipore Corporation) with
a membrane containing 8-μm diameter pores in 300 μl
serum-free RPMI1640. The inserts were then placed into
the bottom chamber wells of a 24-well plate containing
RPMI1640 with 20 % FBS as a chemo-attractant. After
24 h of incubation, cells remaining on the insert top
layer were removed by cotton swab scrubbing, and cells
on the lower surface of the membrane were fixed in
100 % methanol for 15 min, followed by staining with
Giemsa solution. Cell numbers in five random fields
(400×) were counted for each chamber and the average
values were calculated.
For invasion assays, infected cells (1.5 × 105) were
plated in the top chamber with Matrigel-coated mem-
brane (QCM ECMatrix Cell Invasion Assay, Millipore
Corporation), whereas the bottom chambers were filled
with conditioned medium. After 48 h incubation, mi-
grated cells (lower side of the membrane) were counted
as described above.
Immunoblotting
Cells were lysed in RIPA buffer (150 mM NaCl, 10 mM
Tris, pH 7.5, 1 % NP40, 1 % deoxycholate, 0.1 % SDS, pro-
tease inhibitor cocktail (Roche)). Total proteins were frac-
tionated using the NuPAGE 4–12 % Bis-Tris gradient gel
(Invitrogen) and transferred onto PVDF membrane.
Membranes were blocked with 5 % non-fat milk in PBS/
Fig. 1 miR-10b is upregulated in gastric cancer cell lines
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(1:200, Santa Cruz) and β-actin (1:10,000, Abcam).
Immunohistochemistry
Immunohistochemical analysis was performed as previ-
ously described [10]. Sections were incubated with
mouse anti-Hoxd10 (1:50; Santa Cruz) overnight at 4 °C.
The degree of immunostaining was reviewed and scored
independently by two observers based on the proportion
of positively stained tumor cells and intensity of staining.
Tumor cell proportion was scored as follows: 0 (≤5 %
positive tumor cells), 1 (6–25 % positive tumor cells), 2
(26–50 % positive tumor cells), and 3 (>51 % positive
tumor cells). Staining intensity was graded according to
the following criteria: 0 (no staining), 1 (weak staining =
light yellow), 2 (moderate staining = yellow brown), and
3 (strong staining = brown). Staining index was calcu-
lated as the product of staining intensity score and the
proportion of positive tumor cells. Using this method of
assessment, we evaluated Hoxd10 expression in benignTable 1 The number of migratory cells after infected with miR-10b
inhibitor
MKN-28 BGC-823 SGC-7901
miR-10b inhibitor 48.8 ± 3.96 54.2 ± 3.19 35.4 ± 2.07
Negative Control B 98.8 ± 2.59 77.4 ± 2.07 56.2 ± 2.77
Normal Control 107.4 ± 5.27 79.4 ± 3.65 60.2 ± 3.35
t值a 23.62 13.62 13.43
t值b 19.87 11.62 14.09
P值 0.0001 0.0001 0.0001
amiR-10b inhibitor vs Negative Control B
bmiR-10b inhibitor vs Normal Controlgastric epithelia and malignant lesions by determining
the staining index with scores of 0, 1, 2, 3, 4, 6, or 9. The
cutoff value for high and low expression level was
chosen based on a measure of heterogeneity using the
log-rank test with respect to overall survival. An optimal
cutoff value was identified: a staining index score of ≥4
was used to define tumors with high Hoxd10 expression
and a staining index score of ≤3 was used to indicate
low Hoxd10 expression.
Statistical analysis
All statistical analyses were performed using SPSS 16.0
software. Data were analyzed using Student’s t test, while
categorical data were studied using the χ2 or Fisher exact
test. Survival curves were estimated using the Kaplan-
Meier method, and the log-rank test was used toFig. 2 miR-10b inhibits cell migration. Representative fields of
migrated cells on membrane
Fig. 3 The level of Hoxd10 protein in SGC-7901 cells with miR-10b
inhibitor-infected or Negative Control B-infected
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analysis using the Cox proportional hazards regression
model was performed to assess the prognostic values of
protein expression. Correlation coefficients between pro-
tein expression and clinicopathological findings were es-
timated using the Pearson correlation method. Statistical
significance was set at P < 0.05.Fig. 5 Immunohistochemical staining for Hoxd10 in gastric cancer
lesions and noncancerous tissues, magnification 400×. a Hoxd10
was highly expressed in noncancerous tissues. b Hoxd10 was
highly expressed in tubular adenocarcinoma. c Hoxd10 was highly
expressed in poorly differentiated adenocarcinoma. d Hoxd10 was
highly expressed in poorly differentiated adenocarcinoma.Results
miR-10b is upregulated in gastric cancer cell lines
miR-10b was significantly upregulated in AGS, MKN-28,
BGC-823, HCG-27, SGC-7901, and MKN-45 cell lines
(4.7 × 10−4, 1.4 × 10−3, 1.3 × 10−3, 9.8 × 10−4, 8.3 × 10−4,
and 3.7 × 10−4, respectively) compared with the non-
malignant gastric epithelial cell line GES-1 (3.2 × 10−5)
(P < 0.05). The expression of miR-10b did not signifi-
cantly differ between 9811P cells (4.99 × 10−5) and non-
malignant GES-1 cells (3.2 × 10−5) (P > 0.05) (Fig. 1).miR-10b inhibited cell proliferation, migration, and
invasion in vitro
To study the biological role of miR-10b in gastric cancer,
miR-10b inhibitor or Negative Control B was transfected
into MKN-28, BGC-823, and SGC-7901 cells, and miR-
10b levels were evaluated by RT-PCR. miR-10b levels in
SGC-7901, BGC-823, and MKN-28 cells transfected with
miR-10b inhibitor were much lower than in Negative
Control B-infected cells (P < 0.05), 24 h after transfection.
Then, we evaluated the effect of miR-10b on the pro-
liferation of gastric cancer cell lines using MTT assays.
miR-10b inhibitor significantly inhibited proliferation of
MKN-45, BGC-823, and SGC-7901 cells 48 h after
transfection (P < 0.05). miR-10b inhibitor significantly
inhibited proliferation of BGC-823 cells 72 h afterFig. 4 The level of Hoxd10 protein in BGC-823 cells with miR-10b
inhibitor-infected or Negative Control B-infectedtransfection (P < 0.05) but only had a slight effect on the
proliferation of MKN-45 and SGC-7901 cells (P > 0.05).
We further analyzed the effect of miR-10b on the mi-
gratory and invasive behavior of gastric cell lines
(Table 1, Fig. 2). Gastric cancer cells infected with miR-
10b inhibitor displayed significantly lower transmem-
brane migration capacity compared with those infected
with Negative Control B cells and Normal Control cells
48 h after transfection (P < 0.05). No gastric cancer cell
lines transfected with miR-10b inhibitor and Negative
Control B invaded through the membrane of QCM
ECMatrix Cell Invasion Assay 72 h after transfection.
miR-10b directly regulated Hoxd10
To understand the mechanisms by which miR-10b in-
duces tumor invasion and metastasis, Western blotting
for Hoxd10 in SGC-7901 and BGC-823 cells was per-
formed at 72 h post-transfection. Hoxd10 expression
was much higher in cells transfected with miR-10b in-
hibitor than in Negative Control B-infected cells (Figs. 3
and 4).
Expression of Hoxd10 in gastric cancer and
clinicopathological features and prognosis
Hoxd10 was upregulated in 82 (89.13 %) normal gastric
mucosa samples (Fig. 5), and in 242 of 436 (55.5 %)
cases of gastric cancer (Fig. 5). High expression of
Hoxd10 correlated with size of tumor, Lauren classifica-
tion, depth of invasion, lymph node and distant metasta-
sis, and TNM stage (Table 2). We also analyzed the
relationship between Hoxd10 expression and prognosis.
Table 2 Relationship of Hoxd10 expression with pathological parameters of tumor
Clinical parameters HOXD10
Low High t/χ2 P
Age (years) 59.77 ± 12.44 58.48 ± 11.85 1.107 0.269
Gender 0.519 0.4771
Male 135 (43.4 %) 176 (56.6 %)
Female 59 (47.2 %) 66 (52.8 %)
Location 4.379 0.112
Proximal 31 (56.4 %) 24 (43.6 %)
Middle 74 (45.4 %) 89 (54.6 %)
Distal 89 (40.8 %) 129 (59.2 %)
Size 25.716 0.0001
<5 cm 88 (34.4 %) 168 (65.6 %)
≥5 cm 106 (58.9 %) 74 (41.1 %)
Lauren classification 63.165 0.0001
Intestinal 58 (26.0 %) 165 (74.0 %)
Diffuse 136 (63.8 %) 77 (36.2 %)
Histology classification 7.343 0.062
Papillary adenocarcinoma 3 (18.8 %) 13 (81.2 %)
Tubular adenocarcinoma 142 (43.6 %) 184 (56.4 %)
Mucinous adenocarcinoma 17 (58.6 %) 12 (41.4 %)
Signet-ring cell carcinoma 32 (49.2 %) 33 (50.8 %)
Histologic differentiation 5.25 0.154
Well 3 (23.1 %) 10 (76.9 %)
Moderately 50 (39.1 %) 78 (60.9 %)
Poorly 140 (47.8 %) 153 (52.2 %)
Others 1 (50.0 %) 1 (50.0 %)
Invasion depth 33.892 0.0001
T1 9 (15.8 %) 48 (84.2 %)
T2 39 (35.8 %) 70 (64.2 %)
T3 129 (52.9 %) 115 (47.1 %)
T4 17 (65.4 %) 9 (34.6 %)
TNM stages 60.859 0.0001
I 17 (18.9 %) 73 (81.1 %)
II 30 (28.8 %) 74 (71.2 %)
III 102 (59.0 %) 71 (41.0 %)
IV 45 (65.2 %) 24 (34.8 %)
Lymphatic metastasis 45.165 0.0001
No 40 (24.1 %) 126 (75.9 %)
Yes 154 (57.0 %) 116 (43.0 %)
Regional lymph nodes 51.95 0.0001
PN0 40 (24.1 %) 126 (75.9 %)
PN1 67 (49.3 %) 69 (50.7 %)
PN2 65 (65.7 %) 34 (34.3 %)
PN3 22 (62.9 %) 13 (37.1 %)
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Table 2 Relationship of Hoxd10 expression with pathological parameters of tumor (Continued)
Distant metastasis 14.821 0.0001
No 153 (40.8 %) 222 (59.2 %)
Yes 41 (67.2 %) 20 (32.8 %)
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high Hoxd10 protein expression group but was only
24.7 % in the low expression group (χ2 = 60.81, P =
0.001) (Fig. 6). In stages I, II, and III, the 5-year survival
rate of patients with high expression of Hoxd10 was sig-
nificantly higher than those in patients with low expres-
sion. In stage I, the cumulative 5-year survival rate was
91.8 % in the high Hoxd10 expression group but was
only 82.4 % in low expression group (χ2 = 4.25, P =
0.039) (Fig. 7). In stage II, the cumulative 5-year survival
rate was 68.9 % in high Hoxd10 expression group but
was only 53.3 % in low expression group (χ2 = 5.35, P =
0.021) (Fig. 8). In stage III, the cumulative 5-year sur-
vival rate was 40.8 % in high Hoxd10 expression group
but was only 15.7 % in low expression group (χ2 = 12.87,
P = 0.0001) (Fig. 9). In stage IV, the expression of
Hoxd10 did not correlate with the 5-year survival rate,
the cumulative 5-year survival rate was 4.5 % in high
Hoxd10 expression group but was only 2.3 % in low ex-
pression group in stage IV (χ2 = 2.19, P = 0.138) (Fig. 10).
The factors with possible prognostic effects in gastric
carcinoma were analyzed by Cox regression analysis.
The study revealed that lymph node (P = 0.012) and dis-
tant metastases (P = 0.008), TNM stage (P = 0.001), and
expression of Hoxd10 (P = 0.008) were independent
prognostic factors in patients with gastric carcinoma.Fig. 6 Kaplan-Meier curves with univariate analyses (log-rank) for patients wit
tumors in all gastric cancerHowever, age, sex, tumor location and size, histological
classification, tumor differentiation, Lauren’s classifica-
tion, and regional lymph node stage had no prognostic
value.
Discussion
Recent evidence has shown that altered patterns of
microRNA (miRNA) expression correlate with various
human cancers. miR-10b was recently reported to be
dysregulated in some types of cancer and to play a role
in invasion and metastasis. Single microRNA (miRNA)
can regulate expression of several or multiple principal
targets in a specific microenvironment. In different cel-
lular contexts, the same miRNA may exhibit diverse
functions, depending on the repertoire and stoichiom-
etry of its direct mRNA targets [11]. For instance, in
breast cancer, microRNA-10b (miR-10b) promotes inva-
sion and metastasis of tumor cells through regulation of
HOXD10, E-cadherin, and syndecan-1 [12, 13]. miR-10b
may positively regulate the invasion and metastasis of
hepatocellular carcinoma through targeting CADM [8].
miR-10b induces glioma cell invasion by modulating
MMP-14 and uPAR expression via HOXD10 [14].
The oncogenic or tumor suppressive effects of miR-
10b might be tissue specific. Some debate exists on
whether miR-10b is upregulated or downregulated inh simultaneously low Hoxd10 expression versus high Hoxd10 expression
Fig. 7 Kaplan-Meier curves with univariate analyses (log-rank) for patients with low Hoxd10 expression versus high Hoxd10 expression tumors in
all gastric cancer in stage I
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10b to be significantly upregulated in tissues, overex-
pression of miR-10b in gastric cancer tissues was associ-
ated with lymph node and distant metastases, and the
results suggest that miR-10b may play an important role
in gastric tumorigenesis, progression, and prognosis
[16]. However, effects and potential mechanisms of ac-
tion of miR-10b in the metastasis of gastric cancer have
not been explored thoroughly. Here, we discuss a unique
role of miR-10b in gastric cancer cell invasion and me-
tastasis. In this study, we analyzed the level of miR-10b
in human gastric cancer cell lines AGS, MKN-28, BGC-
823, HCG-27, SGC-7901, 9811P, and MKN-45 and in
the non-malignant gastric epithelial cell line GES-1, andFig. 8 Kaplan-Meier curves with univariate analyses (log-rank) for
patients with low Hoxd10 expression versus high Hoxd10 expression
tumors in all gastric cancer in stage IIthe effect of miR-10b expression on gastric cancer cell
proliferation, invasion, and migration. miR-10b was sig-
nificantly upregulated in AGS, MKN-28, BGC-823,
HCG-27, SGC-7901, and MKN-45 cell lines compared
with the non-malignant gastric epithelial cell line GES-1.
Liu et al. found miR-10b was highly expressed in poorly
differentiated gastric cancer cell lines, such as BGC-823
and MKN45 [9]. We further analyzed the effect of miR-
10b on the migratory and invasive behavior of gastric
cell lines (BGC-823, SGC-7901, and MKN-45). miR-10b
inhibitor significantly inhibited proliferation and migra-
tion and also significantly increased the level of Hoxd10
protein in SGC-7901 and BGC-823 cells. Some debate
exists on whether miR-10b is inhibited or increasedFig. 9 Kaplan-Meier curves with univariate analyses (log-rank) for
patients with low Hoxd10 expression versus high Hoxd10 expression
tumors in all gastric cancer in stage III
Fig. 10 Kaplan-Meier curves with univariate analyses (log-rank) for
patients with low Hoxd10 expression versus high Hoxd10 expression
tumors in all gastric cancer in stage IV
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hibitor increased both cell migration and invasion [17].
Inhibition of miR-10b activity by miR-10b inhibitor had
no obvious effects on migration of MNK45 cells, while
severely blocked cell invasion ability [9].
miR-10b can stimulate the upregulation of RhoC and
AKT phosphorylation through targeting HOXD10, thus
promoting cell invasion in gastric tumors [9]. There was
no literature about the relationship between expression
of HOXD10 and prognosis of patients. We further ana-
lyzed the association between Hoxd10 expression and
clinicopathological features and prognosis. Hoxd10 was
overexpressed in gastric cancer and correlated with size
of tumor, Lauren classification, depth of invasion, lymph
node and distant metastasis, TNM stage, and prognosis.
Conclusions
In conclusion, we analyzed the expression of miR-10b in
gastric cancer cell lines, and the effect of miR-10b on
cell proliferation, migration, invasion assays, and
Hoxd10 expression. Results reported here increase the
understanding of the molecular basis of miR-10b in gas-
tric cancer and suggest that miR-10b promotes migra-
tion and invasion through Hoxd10 in human gastric
cancer cell lines. miR-10b may be a useful molecular
biomarker for assessing the risk of gastric cancer devel-
opment, and modulation of miR-10b may represent a
therapeutic approach for treating gastric cancer.
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